abstract：BACKGROUND:Notoriously the treatment of multiple sclerosis (MS) is based on the use of several different drugs, characterized by a diverse mechanism of action, efficacy and safety. Recently, progress has been made towards developing new oral immunotherapies, and dimethyl fumarate is the third oral agent approved for th...

journal_title：Multiple sclerosis and related disorders

authors： Lorefice L,Fenu G,Cabras F,Frau J,Coghe GC,Loi L,Marrosu MG,Cocco E

更新日期：2016-05-01 00:00:00

abstract：:Randomized placebo-controlled clinical trials have been considered the most rigorous method of evaluating the efficacy of novel treatment interventions. The first effective disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) were approved in the 1990s after a number of pivotal placebo-...

journal_title：Multiple sclerosis and related disorders

authors： Solomon AJ,Bernat JL

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Neuromyelitis optica (NMO) is a disabling inflammatory condition that targets astrocytes in the optic nerves and spinal cord. Recent advances led to the individualization of a set of conditions now referred as NMO spectrum disorder (NMOSD). OBJECTIVE:To describe the prevalence and characteristics of NMO SD ...

journal_title：Multiple sclerosis and related disorders

authors： Daoudi S,Bouzar M

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. OBJECTIVE:We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-co...

journal_title：Multiple sclerosis and related disorders

authors： McDonald J,Graves J,Waldman A,Lotze T,Schreiner T,Belman A,Greenberg B,Weinstock-Guttman B,Aaen G,Tillema JM,Hart J,Lulu S,Ness J,Harris Y,Rubin J,Candee M,Krupp LB,Gorman M,Benson L,Rodriguez M,Chitnis T,Mar S

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Fatigue is a common and disabling symptom of multiple sclerosis (MS) patients. Structural changes in several brain areas have been reported to correlate with fatigue in MS patients but none consistently. OBJECTIVE:To study the association between global and regional measures of brain atrophy and fatigue in ...

journal_title：Multiple sclerosis and related disorders

authors： Nourbakhsh B,Azevedo C,Nunan-Saah J,Maghzi AH,Spain R,Pelletier D,Waubant E

更新日期：2016-01-01 00:00:00

abstract：:Currently, there are no approved treatments for NMO. All therapeutic studies in NMO have been either small, retrospective case series or uncontrolled prospective studies. Such studies are susceptible to inherent biases. As a consequence, conclusions regarding efficacy and safety from these studies may be erroneous. Th...

journal_title：Multiple sclerosis and related disorders

authors： Cree BA

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:The promising utility of multi-modality evoked potential batteries to objectively measure multi-tract dysfunction has been evaluated by several groups using different methods. OBJECTIVE:To independently evaluate the use of multi-modality evoked potential batteries as surrogate biomarkers for both physical a...

journal_title：Multiple sclerosis and related disorders

authors： Canham LJ,Kane N,Oware A,Walsh P,Blake K,Inglis K,Homewood J,Witherick J,Faulkner H,White P,Lewis A,Furse-Roberts C,Cottrell DA

更新日期：2015-11-01 00:00:00

abstract：:The clinical presentation of neurosarcoidosis is varied as multiple levels of the neuraxis may be affected. When central nervous system involvement occurs, making an accurate diagnosis of the condition can be challenging, especially given the current definition for definite neurosarcoidosis requires histologic confirm...

journal_title：Multiple sclerosis and related disorders

authors： MacLean HJ,Abdoli M

更新日期：2015-09-01 00:00:00

abstract：INTRODUCTION:The introduction of several new disease-modifying therapies (DMTs) to the field of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a comprehensive understanding of the implications of each new treatment option in order to select the treatment that best suits their patient. An i...

journal_title：Multiple sclerosis and related disorders

authors： Ng P,Murray S,Hayes SM

更新日期：2015-07-01 00:00:00

abstract：:Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...

journal_title：Multiple sclerosis and related disorders

authors： Barroso B,Miquel M,Marasescu R,Demasles S,Krim E,Bonnan M

更新日期：2015-07-01 00:00:00

abstract：:Acute relapses continue to be a significant aspect of multiple sclerosis (MS) on both the epidemiologic level and the individual patient level. Past work demonstrates residual disability from relapses as well as high patient-reported rates of ineffective relapse treatment. To better characterize the impact of MS relap...

journal_title：Multiple sclerosis and related disorders

authors： Nickerson M,Cofield SS,Tyry T,Salter AR,Cutter GR,Marrie RA

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:There is no evidence that disease modifying therapies (DMTs) are beneficial in progressive (non-relapsing) MS. However, these patients may benefit from multidiscipliniary interventions, and require financial and community support. Non-pharmacological needs of MS patients may be overlooked during fund allocat...

journal_title：Multiple sclerosis and related disorders

authors： Lonergan R,Kinsella K,Fitzpatrick P,Duggan M,Jordan S,Bradley D,Hutchinson M,Tubridy N

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:We explored health-related quality of life (HRQoL) and psychosocial aspects in a cohort of patients with a history of longstanding benign MS (BMS). METHODS:Patients with BMS (EDSS≤3 after 20 years disease duration) were re-assessed 25-30 years post-MS symptom onset for: EDSS, HRQoL (MSQoL-54), depression (B...

journal_title：Multiple sclerosis and related disorders

authors： Bueno AM,Sayao AL,Yousefi M,Devonshire V,Traboulsee A,Tremlett H

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Interferon-beta (IFNβ) is currently the most used disease-modifying treatment for relapsing-remitting multiple sclerosis (RRMS), but it can lead to the production of neutralising antibodies (NABs) against IFNβ. CLINICAL CASE:A lady with a past history of genital herpes was diagnosed with RRMS, started IFN...

journal_title：Multiple sclerosis and related disorders

authors： Fine D,Dattani A,Moreira I,Giovannoni G,Marta M

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:Determine whether MRI activity 6 months after treatment initiation in the Controlled High-Risk Subjects Avonex® Multiple Sclerosis Prevention Study (CHAMPS) predicted progression to clinically definite multiple sclerosis (CDMS) over the subsequent 30 months in intramuscular interferon beta-1a (IM IFNβ-1a)-tre...

journal_title：Multiple sclerosis and related disorders

authors： Kinkel RP,Simon JH,O'Connor P,Hyde R,Pace A

更新日期：2014-11-01 00:00:00

abstract：BACKGROUND:Prediction of the course of multiple sclerosis (MS) was traditionally based on features close to onset. OBJECTIVE:To evaluate predictors of the individual risk of secondary progression (SP) identified at any time during relapsing-remitting MS. METHODS:We analysed a database comprising an untreated MS incid...

journal_title：Multiple sclerosis and related disorders

authors： Skoog B,Tedeholm H,Runmarker B,Odén A,Andersen O

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Disturbances that occur in patients with multiple sclerosis (MS) are not restricted to motor, sensory, or urinary functions; they also include cognitive dysfunction, fatigue, and depression. Moreover, people with MS are known to have fewer social activities and a reduced quality of life. One aspect of social...

journal_title：Multiple sclerosis and related disorders

authors： Berneiser J,Wendt J,Grothe M,Kessler C,Hamm AO,Dressel A

更新日期：2014-07-01 00:00:00

abstract：BACKGROUND:Cognitive impairment and psychiatric symptoms impact many aspects of the lives of people with multiple sclerosis [MS]. This literature is based largely on North American and Western European samples, and little is known about these aspects of MS disability in Latin America. OBJECTIVE:RELACCEM is a longitudi...

journal_title：Multiple sclerosis and related disorders

authors： Caceres F,Vanotti S,Benedict RH,RELACCEM Work Group.

更新日期：2014-05-01 00:00:00

abstract：:We present a 26 year old Pakistani lady with first presentation of a demyelinating event, presenting as Parinaud's syndrome. The video demonstrates a convergence-retraction nystagmus on upgaze and failure of accommodation, and her brain imaging confirms a corresponding pre-tectal contrast enhancing T2 hyperintense les...

journal_title：Multiple sclerosis and related disorders

authors： Gnanapavan S,Sillery E,Acheson JF,Toosy AT

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:MS imposes a significant burden on patients, caregivers, employers, and the healthcare system. OBJECTIVE:To comprehensively evaluate the US MS burden using nationally representative data from the Medical Expenditure Panel Survey. METHODS:We identified non-institutionalized patients aged ≥18 with MS (ICD-9 ...

journal_title：Multiple sclerosis and related disorders

authors： Campbell JD,Ghushchyan V,Brett McQueen R,Cahoon-Metzger S,Livingston T,Vollmer T,Corboy J,Miravalle A,Schreiner T,Porter V,Nair K

更新日期：2014-03-01 00:00:00

abstract：:Lay-members of the public are often involved in grant and ethics review panels. Furthermore grant applications/reports all require some form of lay summary. In response to critical remarks from people with multiple sclerosis (MS) about using the term 'sufferer' as a descriptor, a series of surveys using the internet/s...

journal_title：Multiple sclerosis and related disorders

authors： Baker D,Pepper G,Yauner F,Giovannoni G

更新日期：2014-01-01 00:00:00

abstract：OBJECTIVE:Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. BACKGROUND:Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The en...

journal_title：Multiple sclerosis and related disorders

authors： Thaera GM,Wingerchuk DM,Carter JL

更新日期：2014-01-01 00:00:00

abstract：INTRODUCTION:Given that vitamin D has a role in immunomodulation, and its levels appear to correlate with the development of Multiple Sclerosis (MS), it is conceivable that vitamin D may also influence disease activity in MS patients. In this regard, we conducted a systematic review investigating the evidence for: (1) ...

journal_title：Multiple sclerosis and related disorders

authors： Ganesh A,Apel S,Metz L,Patten S

更新日期：2013-10-01 00:00:00

abstract：:This report presents the 4th documented case worldwide of herpes simplex encephalitis in multiple sclerosis (MS) patients treated with natalizumab and the first case in the UK. Natalizumab is licensed for relapsing remitting multiple sclerosis in patients with high disease activity despite treatment with interferon-be...

journal_title：Multiple sclerosis and related disorders

authors： Sharma K,Ballham SA,Inglis KE,Renowden S,Cottrell DA

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:Different walking capacity test formats are applied, but their impact on the gait pattern in persons with MS (pwMS) has not yet been investigated according to baseline velocity performance. OBJECTIVE:To assess, in pwMS with different ambulation dysfunction, the impact of speed instructions and previous walk...

journal_title：Multiple sclerosis and related disorders

authors： Feys P,Severijns D,Vantenderloo S,Knuts K,Hannes D,Gijbels D,Wens I

更新日期：2013-07-01 00:00:00

abstract：UNLABELLED:Both female and male persons with MS are at increased risk for various forms of physical, sexual, and disability-specific abuse. An ongoing study revealed a subset of respondents in which the caregiver acknowledged mistreatment of the person with MS, but that person either denied or minimized mistreatment M...

journal_title：Multiple sclerosis and related disorders

authors： Shapiro J,Wiglesworth A,Morrison EH

更新日期：2013-04-01 00:00:00

abstract：:Neural cell adhesion molecule (NCAM) has been studied extensively. But it is only in recent times that interest in this molecule has shifted to conditions such as Alzheimer's disease, Multiple Sclerosis and Schizophrenia, focusing on its role in neurodegeneration and abnormal neurodevelopment. NCAM is important in neu...

journal_title：Multiple sclerosis and related disorders

authors： Gnanapavan S,Giovannoni G

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Natural history studies have typically focused on non-modifiable factors as predictors of disability progression in multiple sclerosis (MS). Weight status has emerged as a correlate of disability status in cross-sectional studies of persons with MS and represents a possible modifiable predictor of disability...

journal_title：Multiple sclerosis and related disorders

authors： Pilutti LA,McAuley E,Motl RW

更新日期：2012-07-01 00:00:00

abstract：BACKGROUND:Fatigue, depression, and physical inactivity are common in multiple sclerosis (MS), but there is limited information on the bi-directional associations among those variables over a long period of time. OBJECTIVE:This study examined the hypothesis that fatigue and depression would predict change in physical ...

journal_title：Multiple sclerosis and related disorders

authors： Motl RW,Suh Y,Weikert M,Dlugonski D,Balantrapu S,Sandroff B

更新日期：2012-01-01 00:00:00